Cyclophosphamide
Anal Squamous Cell Carcinoma
SCG Cell Therapy Pte. Ltd.Small moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 40/ 100
- Competitive Position
- 89/ 100
Competitive context
27 Active assets in the Anal Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM Columbia University | Phase 2 | BB |
Carboplatin Fudan University | Phase 3 | BB |
Nivolumab National Cancer Institute (NCI) | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 | BB |
Atezolizumab Oncolytics Biotech | Phase 2 | B |
View all 39 →
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →